Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study (opcemisa) of the Combination of ISA101b and Cemiplimab Versus Cemiplimab for Recurrent/metastatic (R/M) HPV16-positive Oropharyngeal Cancer (OPC).
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined